Before therapy, 37 percent of men reported at least some degree of impairment in sexual desire, while 44 percent reported dissatisfaction with their sexual life.
In addition, 22 percent reported impairment
in erectile and 26 percent
in ejaculatory function. The average onset of sexual dysfunction appeared to be within four weeks of starting antiviral therapy, and many patients reported a gradual worsening over time.